Managing radicular spine pathology requires balancing neural decompression with durable osseous arthrodesis. For years, spine clinicians have expressed concern regarding chronic gabapentinoid use in patients scheduled for spinal fusion. Because basic science research suggests that voltage-gated calcium channel modulators impede osteoblastogenesis, surgeons frequently worry about delayed fusion and pseudarthrosis. Furthermore, conflicting reports exist regarding perioperative opioid consumption and functional outcomes. A landmark cohort study provides reassuring real-world evidence, demonstrating that long-term preoperative therapy does not compromise two-year revision rates or overall patient recovery.

Preoperative Radiculopathy and Chronic Gabapentinoid Use

Lumbar spondylosis, disc herniation, and spinal canal stenosis frequently cause debilitating compressive radiculopathy. Consequently, physicians prescribe alpha-2-delta ligands, specifically gabapentin and pregabalin, as primary non-opioid pharmacotherapy. These agents attenuate calcium influx at presynaptic nerve terminals. Therefore, they effectively suppress central neuronal sensitization and relieve neuropathic symptoms. However, many candidates for elective arthrodesis remain on these medications for months or years prior to operative intervention.

Recent clinical evaluations analyzed 461 adult patients who underwent elective one-level or two-level lumbar fusion between 2017 and 2022. Among these surgical candidates, 13.2 percent maintained chronic preoperative gabapentin prescriptions, while 10.2 percent received pregabalin. Crucially, baseline demographics, body mass index, comorbid medical profiles, and surgical complexity remained well balanced across the study groups. Thus, this investigation offers an objective framework to assess whether sustained drug exposure alters clinical recovery. Although animal models suggested impaired osteogenic healing, translational clinical data had remained scarce until now.

Investigating Arthrodesis Integrity and Reoperation Rates

Spine surgeons prioritize successful solid arthrodesis to prevent chronic mechanical instability and hardware failure. In experimental animal models, pregabalin significantly reduced bone mineral density and inhibited histologic posterolateral bridging. Therefore, surgeons feared that chronic preoperative exposure would escalate pseudarthrosis rates in human subjects.

Nevertheless, the retrospective cohort data revealed no statistically significant differences in revision surgery rates at two years. Patients with chronic exposure experienced identical reoperation rates compared to medication-naive peers. Specifically, mechanical hardware loosening, pseudarthrosis-related revisions, and surgical site complications occurred at equivalent frequencies across all cohorts. Furthermore, surgical approach and fusion level complexity did not modify these results. These objective findings provide immense reassurance for orthopedic and neurological spine teams. Consequently, clinicians do not need to consider preoperative exposure as an automatic barrier to successful fusion. Surgeons can proceed with standard interbody instrumentation without expecting elevated nonunion rates.

Perioperative Opioid Requirements and MME Differences

Controlling acute perioperative pain represents a cornerstone of modern enhanced recovery after surgery protocols. Interestingly, the study uncovered notable differences in total morphine milligram equivalents consumed by patients. Individuals chronically taking pregabalin consumed significantly higher total opioid amounts compared to those taking gabapentin. In addition, pregabalin users required greater cumulative opioids than gabapentinoid-naive individuals.

Specifically, the pregabalin cohort consumed an average of 132 morphine milligram equivalents, whereas gabapentin users required 104 equivalents. Nongabapentinoid patients utilized only 90.3 equivalents during the acute postoperative phase. However, state prescription monitoring data confirmed that preoperative baseline opioid consumption sixty days prior to surgery remained virtually identical across groups. Therefore, altered pharmacodynamics or differences in receptor affinity likely explain this variance. Pregabalin possesses linear oral bioavailability and potent receptor affinity. Consequently, long-term exposure may induce unique neuroreceptor downregulation, diminishing acute multimodal analgesic efficacy. Clinicians must anticipate these higher requirements when designing individualized postoperative analgesic strategies.

Patient-Reported Outcome Measures Across Clinical Follow-Up

Evaluating functional recovery through validated patient-reported outcome measures ensures an authentic assessment of clinical success. Investigators gathered longitudinal scores, including visual analog scales for back and leg pain and Oswestry Disability Index ratings. Initially, unadjusted bivariate analyses demonstrated a difference in back pain improvement at six months between the cohorts.

However, subsequent pairwise statistical comparisons revealed no significant residual differences. Furthermore, rigorous multivariate regression confirmed that chronic preoperative drug usage was not an independent predictor of back pain scores. Similarly, leg pain reduction, functional mobility, and physical disability scores remained comparable between exposed patients and non-users across all timepoints. In addition, physical recovery trajectories tracked identically through two years of prospective clinical observation. As a result, patients achieved meaningful relief from radicular pain irrespective of their previous pharmacotherapy. These patient-centered outcomes demonstrate that preoperative neuromodulatory regimens do not compromise postoperative functional restoration.

Translating Preclinical Fears to Clinical Spine Practice

Basic science research often provides vital mechanistic insights, yet translational discrepancies frequently arise in clinical medicine. In rodent models, researchers observed that high-dose pregabalin suppressed osteoblast proliferation, alkaline phosphatase activity, and collagen synthesis. Consequently, laboratory investigators warned that gabapentinoids could severely disrupt spinal arthrodesis.

However, human surgical biology incorporates robust host factors that counteract subtle cellular inhibitions. First, surgeons utilize rigid modern instrumentation that provides superior mechanical stabilization and compression. Second, effective decortication and advanced osteobiologic grafts deliver concentrated osteoinductive signals. Moreover, human therapeutic dosages remain substantially lower on a milligram-per-kilogram basis than the toxic concentrations administered in rodent experiments. Thus, cellular impairments documented in isolated culture environments do not translate directly into clinical pseudarthrosis. Spine teams can confidently explain these distinctions to worried patients. Evidence-based medicine demonstrates that therapeutic doses do not prevent sound radiographic bone bridge formation.

Perioperative Management Strategies for Spine Surgeons

These findings carry direct practical implications for daily surgical planning. Historically, some clinicians attempted rapid preoperative drug discontinuation to protect bone fusion. However, abrupt cessation of gabapentinoids precipitates severe physiological withdrawal, causing rebound diaphoresis, tachycardia, insomnia, and acute hyperalgesia. Therefore, surgeons should never discontinue these agents precipitously before elective fusion.

Instead, surgical teams should maintain stable regimens through the immediate preoperative period. In addition, anesthesiologists must acknowledge the distinct opioid requirements of pregabalin users. Because these patients exhibit greater opioid consumption postoperatively, teams should implement targeted multimodal analgesia, including acetaminophen, ketamine, and local fascial plane blocks. Furthermore, clinicians can initiate gradual outpatient drug tapering once surgical decompression resolves the primary nerve root compression. Ultimately, this balanced approach preserves patient comfort, prevents withdrawal crises, and maintains excellent long-term surgical success.

Does chronic gabapentinoid use increase lumbar revision surgery risk?

Current clinical evidence demonstrates that chronic gabapentinoid use does not increase two-year surgical revision rates following elective lumbar fusion. Although preclinical animal studies raised concerns regarding impaired osteoblast activity and delayed bone healing, clinical data show that long-term preoperative exposure does not compromise pseudarthrosis rates or overall surgical durability.

Why did pregabalin patients show higher postoperative opioid consumption?

Patients receiving chronic pregabalin consumed significantly higher morphine milligram equivalents postoperatively compared to gabapentin and non-user groups. Clinicians hypothesize that this observation reflects heightened central sensitization, greater baseline neural compression, or differing pharmacokinetics. However, preoperative baseline opioid consumption sixty days prior to surgery remained comparable across all patient cohorts.

Should spine surgeons discontinue gabapentinoids before elective lumbar fusion?

Spine teams do not need to routinely discontinue preoperative gabapentinoids solely out of concern for bone fusion failure. However, clinicians must avoid abrupt cessation, which precipitates severe autonomic withdrawal symptoms. Instead, surgical teams should optimize multimodal analgesic plans, monitor postoperative sedation closely, and coordinate stepwise postoperative medication tapering when appropriate.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should exercise independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Dalton J et al. Impact of Chronic Preoperative Gabapentinoid Exposure on Surgical and Patient-Reported Outcome Measures Following Lumbar Fusion. Spine (Phila Pa 1976). 2026 Feb 01. doi: 10.1097/BRS.0000000000005338. PMID: 40104951.
2. Khurana G, Jindal P, Sharma JP, Bansal KK. Postoperative pain and long-term functional outcome after administration of gabapentin and pregabalin in patients undergoing spinal surgery. Spine (Phila Pa 1976). 2014;39(6):E363-E368. doi: 10.1097/BRS.0000000000000185.
3. Canos A, Cort L, Fernández Y, et al. Preventive analgesia with pregabalin in neuropathic pain from "failed back surgery syndrome": assessment of sleep quality and disability. J Pain Res. 2016;9:831-839. doi: 10.2147/JPR.S118949.